CAR T-Cell Therapy and the Patient Experience

Join Elissa Baldwin of the LLS Patient Education team as she speaks to Olaleken Oluwole, MBBS, MD and Brittney Baer, BSN, RN, of Vanderbilt University Medical Center in Nashville, TN about CAR T-cell therapy. In this episode we discuss this groundbreaking therapy as well as after care for patients.
Supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Johnson & Johnson & Legend Biotech; Kite, a Gilead Company; and Novartis Pharmaceuticals Corp.

[@laradamico1991]

My husband had car t for lymphoma B cell. He had to stay in the hospital for 41 days. Thought it worked. Scans were good for four months, then came back with a vengeance. He was dead 8 months after car t. It was a grueling experience for such a short term result.